Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
REGN News
announced a major expansion of its manufacturing capacity, including a $3 billion deal with Fujifilm Diosynth Biotechnologies and further investments at its Tar...
Regeneron Pharmaceuticals, Inc. REGN on Tuesday announced a significant expansion of its manufacturing capacity through a new agreement with FUJIFILM Diosynth B...
Sanofi ( (SNY) ) has issued an update. On April 18, 2025, Sanofi announced that the US FDA approved Dupixent as the first new targeted therapy in over a decade...
Analyst ratings
73%
of 26 ratingsMore REGN News
As previously reported, Cantor Fitzgerald analyst Carter Gould upgraded Regeneron (REGN) to Overweight from Neutral with a price target of $695, down from $800,...
Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst John Newman from Canaccord Genuity main...
Canaccord analyst John Newman lowered the firm’s price target on Regeneron (REGN) to $850 from $1,152 and keeps a Buy rating on the shares. The firm said they a...
Regeneron (REGN) Pharmaceuticals announced on Friday the Food and Drug Administration has issued a complete response letter regarding the supplemental biologics...
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of adults and ado...